Jeffrey W. Taub

Jeffrey W. Taub, M.D.
Division of Hematology Oncology
Children's Hospital of MI

Research Description:
Dr. Taub's research has focused on studying the molecular epidemiology and pharmacology of childhood leukemia, the most common form of cancer in children and the leading cause of death from disease of American children. Using a unique source of blood samples collected at birth and used for genetic screening ("Guthrie cards"), his lab is screening for the presence of preleukemic clones (by PCR-based minimal residual disease assays) in the blood samples of children who subsequently developed leukemia. This would confirm a prenatal origin of leukemia and potential in utero exposures being linked to the development of leukemia. These studies are also examining factors including differences in folate metabolism which may account for the 2-3-fold higher incidence of acute lymphoblastic leukemia (ALL) in Caucasian compared to African American children in the United States. Another project in the laboratory is studying the biology of acute myeloid leukemia (AML) in children with Down syndrome. Children with Down syndrome have a 20-fold greater risk of developing leukemia compared to children without Down syndrome, and have the highest cure rate (80-100%) of any subgroup of AML patients. These studies use both primary clinical samples from patients diagnosed with AML, as well as clinically relevant leukemia cell lines, to examine the roles of both chromosome 21-localized and non-chromosome 21-localized genes in leukemogenesis and the metabolism of chemotherapy drugs. Findings from these studies are also being applied to developing new leukemia therapies in clinical trials for children without Down syndrome.

Selected Publications:

Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma. Pediatr Blood Cancer. 2014 Oct 12. [Epub ahead of print]

Xie C, Edwards H, Caldwell JT, Wang G, Taub JW, Ge Y. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2014:S1574-7891-00232-4.

Caldwell JT, Ge Y, Taub JW. Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Rev Hematol. 2014 Sep 18:1-10. [Epub ahead of print]

Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H. Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol. 2014 Aug 28. [Epub ahead of print]

Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014;7:53.

Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer. 2014;61:1767-73.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014;120:2482-9.

Harper FW, Goodlett BD, Trentacosta CJ, Albrecht TL, Taub JW, Phipps S, Penner LA. Temperament, personality, and quality of life in pediatric cancer patients. J Pediatr Psychol. 2014;39:459-68.

Peterson AM, Harper FW, Albrecht TL, Taub JW, Orom H, Phipps S, Penner LA. Parent caregiver self-efficacy and child reactions to pediatric cancer treatment procedures. J Pediatr Oncol Nurs. 2014;31:18-27.

Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2014;26:149-61.

Taub JW. Neonatal GATA1 mutant clones under the radar. Blood. 2013;122:3851-3.

Xie C, Drenberg C, Edwards H, Caldwell JT, Chen W, Inaba H, Xu X, Buck SA, Taub JW, Baker SD, Ge Y. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One. 2013;8:e79106.

Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2013 Oct 16.

Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z. Panobinostat synergistically enhances the cytotoxic effects of Cisplatin, Doxorubicin or Etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8:e76662.

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. 2013 Sep 4.

Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood. 2013 Aug 26.

Caldwell JT, Edwards H, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. PLoS One. 2013;8:e68601.

Hales EC, Orr SM, Larson Gedman A, Taub JW, Matherly LH. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem. 2013;288:22836-48.

Harper FW, Peterson AM, Uphold H, Albrecht TL, Taub JW, Orom H, Phipps S, Penner LA. Longitudinal study of parent caregiving self-efficacy and parent stress reactions with pediatric cancer treatment procedures. Psychooncology. 2013 ;22:1658-64.

Education and Training:
MD (1987): University of Western Ontario, London, Ontario, Canada
Transitional Internship (1987-1988): Victoria Hospital, London, Ontario, Canada
Pediatric Residency (1988-1991): Children's Hospital of Michigan, Detroit, Michigan
Fellowship in Pediatric Hematology/Oncology (1991-1994): Children's Hospital of Michigan, Detroit, Michigan

Cancer Biology Courses Taught:
CB7240 Principles of Cancer Therapy